Memantin Grindeks (Memantine Hydrochloride)

Memantine is a non‑competitive antagonist of the NMDA receptor. It blocks excessive calcium influx caused by prolonged glutamate activation, reducing excitotoxic neuronal damage while preserving normal neurotransmission essential for learning and memory.

The prescribed dose of memantine is individualized by the treating physician based on the patient’s clinical condition, renal function and tolerability. Dosage adjustments and titration schedules are determined by the healthcare professional and should follow local prescribing information.

The safety of memantine in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the Memantin Grindeks product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil, rivastigmine and galantamine, which increase acetylcholine levels. Memantine is typically used in moderate to severe disease or as add‑on therapy, offering a distinct mechanism that targets excitotoxicity rather than cholinergic deficiency.

Store the product at room temperature, below 25 °C, in the original container. Protect it from moisture and direct sunlight to maintain stability. Do not refrigerate or freeze the tablets unless otherwise directed by the manufacturer.

Memantin Grindeks is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious adverse events, although uncommon, include seizures, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be monitored for signs of these reactions, and treatment should be discontinued promptly if they occur.

Memantine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in pregnant or breastfeeding women unless clearly justified.